Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET

Ohlsson, Håkan LU orcid ; Gålne, Anni LU orcid ; Trägårdh, Elin LU orcid ; Malmström, Marlene LU orcid ; Sundlöv, Anna LU orcid and Almquist, Martin LU (2022) In Journal of Neuroendocrinology 34(6).
Abstract

For patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET), health-related quality of life (HRQoL) is important. Meanwhile, whether tumour volume is associated with HRQoL is unknown. Hence, the aim of this study was to assess if total somatostatin receptor expressing tumour volume is correlated with HRQoL in patients with metastatic GEP-NET. Some 71 patients were included in the study. HRQoL and NET-specific symptoms were assessed with EORTC QLQ-C30 and EORTC GI.NET21. A summary score was calculated from the output of the QLQ-C30. Total somatostatin receptor expressing tumour volume was retrospectively evaluated on somatostatin receptor imaging with positron emission tomography-computed tomography... (More)

For patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET), health-related quality of life (HRQoL) is important. Meanwhile, whether tumour volume is associated with HRQoL is unknown. Hence, the aim of this study was to assess if total somatostatin receptor expressing tumour volume is correlated with HRQoL in patients with metastatic GEP-NET. Some 71 patients were included in the study. HRQoL and NET-specific symptoms were assessed with EORTC QLQ-C30 and EORTC GI.NET21. A summary score was calculated from the output of the QLQ-C30. Total somatostatin receptor expressing tumour volume was retrospectively evaluated on somatostatin receptor imaging with positron emission tomography-computed tomography (68Ga-DOTA-TATE/TOC PET-CT) in each patient. Simple and multiple linear regression were used to evaluate the correlation between tumour volume and HRQoL, controlling for potential confounders. No correlation was found between total somatostatin receptor expressing tumour volume and QLQ-C30 summary score. Weak positive correlations were found between total tumour volume and the specific symptoms dyspnoea, diarrhoea and flushing. To the best of our knowledge, this is the first study to evaluate the association between total somatostatin expressing tumour volume and HRQoL. Our results indicate that, while tumour volume is weakly associated with symptom severity of the carcinoid syndrome, other factors might impact more on overall HRQoL.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
health-related quality of life, neuroendocrine tumours, somatostatin receptor imaging, tumour volume
in
Journal of Neuroendocrinology
volume
34
issue
6
publisher
Wiley-Blackwell
external identifiers
  • pmid:35488399
  • scopus:85129120550
ISSN
0953-8194
DOI
10.1111/jne.13139
project
PET-CT imaging of neuroendocrine tumors - Beyond diagnostics
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2022 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
id
805c2838-1f96-480e-a44b-fea276ce69ae
date added to LUP
2022-06-03 17:21:44
date last changed
2024-12-27 14:49:44
@article{805c2838-1f96-480e-a44b-fea276ce69ae,
  abstract     = {{<p>For patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET), health-related quality of life (HRQoL) is important. Meanwhile, whether tumour volume is associated with HRQoL is unknown. Hence, the aim of this study was to assess if total somatostatin receptor expressing tumour volume is correlated with HRQoL in patients with metastatic GEP-NET. Some 71 patients were included in the study. HRQoL and NET-specific symptoms were assessed with EORTC QLQ-C30 and EORTC GI.NET21. A summary score was calculated from the output of the QLQ-C30. Total somatostatin receptor expressing tumour volume was retrospectively evaluated on somatostatin receptor imaging with positron emission tomography-computed tomography (<sup>68</sup>Ga-DOTA-TATE/TOC PET-CT) in each patient. Simple and multiple linear regression were used to evaluate the correlation between tumour volume and HRQoL, controlling for potential confounders. No correlation was found between total somatostatin receptor expressing tumour volume and QLQ-C30 summary score. Weak positive correlations were found between total tumour volume and the specific symptoms dyspnoea, diarrhoea and flushing. To the best of our knowledge, this is the first study to evaluate the association between total somatostatin expressing tumour volume and HRQoL. Our results indicate that, while tumour volume is weakly associated with symptom severity of the carcinoid syndrome, other factors might impact more on overall HRQoL.</p>}},
  author       = {{Ohlsson, Håkan and Gålne, Anni and Trägårdh, Elin and Malmström, Marlene and Sundlöv, Anna and Almquist, Martin}},
  issn         = {{0953-8194}},
  keywords     = {{health-related quality of life; neuroendocrine tumours; somatostatin receptor imaging; tumour volume}},
  language     = {{eng}},
  number       = {{6}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Journal of Neuroendocrinology}},
  title        = {{Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET}},
  url          = {{http://dx.doi.org/10.1111/jne.13139}},
  doi          = {{10.1111/jne.13139}},
  volume       = {{34}},
  year         = {{2022}},
}